Skip to main content

CRDL · Cardiol Therapeutics Inc.

Track CRDL — free
$0.96 +0.01 (+1.04%)
Market Cap
$112.71M
Shares
127.69M
Volume · Nov 19 936.75K Avg daily vol (3M) 1.21M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.88 Open$0.95 Day$0.87–0.95 52W close$0.88–2.29 Avg vol 30d685K Short int2.6M · 2.0% of shares · 4.3d Short vol28% DataJan 2020–Nov 2026

Latest documents

2026
Nov 12
Current report 6-K
US$75,000,000 ATM program established

Cardiol Therapeutics Inc. reported nine-month net loss of 30,225,020 and cash and cash equivalents of 29,229,802 at September 30, 2026. It established a US$75,000,000 ATM program with Jefferies LLC and raised US$4.55 million afterward.

Read from the first part of this long document
6 source passages
CARDIOL THERAPEUTICS INC. Cash and cash equivalents<br>(note 3) | | 29,229,802 | | 21,416,684 Net<br>loss and comprehensive loss for the period | | (30,225,020) | | (26,606,305) Under the terms of the 2026 ATM Program, the Corporation may, from time to time, sell common shares (the “Offered Shares”) having an aggregate value of US$75,000,000 through the Sales Agent on the Nasdaq Capital Market. Subsequent to September 30, 2026, the Corporation announced it has entered into a sales agreement with Jefferies LLC (the “Sales Agent”) acting as agent in connection with the 2026 at-the-market offering program (the “2026 ATM Program”). Subsequent to September 30, 2026, US$4.55 million of gross proceeds was raised under the 2026 ATM Program. Open the document at this passage
Nov 3
Current report 6-K
US$75,000,000 common share sale agreement

Cardiol Therapeutics Inc. agreed with Jefferies LLC to issue and sell common shares with an aggregate offering price of up to US$75,000,000.

Read from the first part of this long document
Source passage
Cardiol Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”) to issue and sell common shares of the Company (the “Common Shares”) having an aggregate offering price of up to US$75,000,000 (the “Shares”) upon and subject to the terms and conditions contained herein. Open the document at this passage
Nov 3
Current report 6-K
US$75 million ATM equity program launched

Cardiol Therapeutics Inc. entered an agreement with Jefferies LLC to offer and sell up to US$75 million under an at-the-market program. The company has no obligation to sell any shares, and proceeds would support CardiolRx and CRD-38 development.

4 source passages
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales Agent") for an at-the-market offering program (the "ATM Program"). The ATM Agreement will allow the Company to offer and sell up to US$75 million of common shares of the Company (the "Offered Shares") under the ATM Program. The timing and extent of the use of the ATM Program will be at the discretion of the Company, and the Company has no obligation to sell any shares pursuant to the ATM Program. As outlined in the Supplement, the Company intends to use the net proceeds of any such sales under the ATM Program to support the development of CardiolRx™ for the treatment of recurrent pericarditis including, subject to the Phase III MAVERIC trial outcomes, supporting a New Drug Application, to support the clinical development of CRD-38 and for general and administrative expenses, working capital and other expenses. Open the document at this passage
Sep 23
Current report 6-K
Current report

Cardiol Therapeutics Inc. reached 110-patient MAVERIC enrollment target ahead of schedule and plans expansion to up to 150 patients after fewer-than-expected recurrences. Topline results are anticipated in mid-2027, versus previous Q1 2027 guidance; cash runway extends into Q1 2028.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.4%
Year over year · more shares
Price change (1Y)
-7.8%
Trailing year
Short interest
2.0%
Latest settlement · 4.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −32%
below
Price vs 50-day avg −33%
below
RSI (14) 27
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −28%
trailing
YTD return −7%
this year
Relative strength −22%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.03% of shares out · ▼ -8.7% MoM · 4.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
59 holders — near 3-yr high, broad support
Squeeze score 51
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −61%
past year
ATR 8.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−32% Bearish
Price vs 50-day avg
−33% Bearish
RSI (14)
27 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.03% of shares out · ▼ -8.7% MoM · 4.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
59 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $2
vs 200-day avg -32% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRDL
Cardiol Therapeutics Inc.
this stock
$112.71M -7.5% — — 2.0%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
59
% held
31.8%
Net QoQ
+11.1M sh
Top holder
MMCAP International Inc.…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
2.6M
Days to cover
4.3d
Change
-248.3K sh
View
Short Volume
Short vol %
28%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
5.3K
Value
$6.2K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
60.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 12, 2026
This year
35

Cardiol Therapeutics Inc. reported nine-month net loss of 30,225,020 and cash and cash equivalents of 29,229,802 at September 30, 2026. It established a US$75,000,000 ATM program with Jefferies LLC and raised US$4.55 million afterward.

View
Exempt Offerings
Offering
$8.5M
Filed
Nov 4, 2025
View
Earnings & Events
Webcasts
Last webcast
Sep 14, 2026
View
Investor Relations
Latest news
Cardiol Therapeutics Announces At…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
CRDL -15.1% -23.2% -27.7% -20.5% -7.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -9.7% -17.0% -22.0% -15.2% -12.5%
Key facts CIK 1702123 CUSIP 14161Y200 13F (30d) 58 filings 56 filers Visit website Investor relations